The effects of once-daily saquinavir/minidose ritonavir on the pharmacokinetics of methadone. 2004

Mark J Shelton, and Denise Cloen, and Robin DiFrancesco, and Charles S Berenson, and Andrew Esch, and Pascal J de Caprariis, and Branka Palic, and Jane L Schur, and Christopher J L Buggé, and Anders Ljungqvist, and Orlando Espinosa, and Ross G Hewitt
GlaxoSmithKline, Five Moore Drive, P.O. Box 13398, Research Triangle Park, NC 27709, USA.

Twelve methadone-maintained HIV-negative subjects were given saquinavir/ritonavir (SQV/rtv) 1600 mg/100 mg once daily for 14 days. Pharmacokinetic evaluations of total and unbound methadone enantiomers (R and S) were conducted before and after SQV/rtv. SQV/rtv was well tolerated, with no ACTG Grade 3-4 adverse events, no evidence of sedation, and no changes in methadone dose. For R-methadone (active isomer), C(max), AUC(0-24 h), and C(min) were unchanged, but percent unbound 4 hours after dosing was reduced by 12%. For S-methadone, no differences in pharmacokinetic parameters of total drug were seen, but unbound concentrations were reduced by 15% and 21% at 4 and 24 hours after dosing, respectively. SQV trough concentrations exceeded the anticipated EC(50) (50 ng/mL) in 10/12 subjects, persisting for at least 6 hours after the final dose in 4/6 subjects. Once-daily SQV/rtv in methadone-maintained subjects is safe and not associated with any clinically significant interaction with methadone during 14 days of concomitant administration.

UI MeSH Term Description Entries
D008297 Male Males
D008657 Metabolic Clearance Rate Volume of biological fluid completely cleared of drug metabolites as measured in unit time. Elimination occurs as a result of metabolic processes in the kidney, liver, saliva, sweat, intestine, heart, brain, or other site. Total Body Clearance Rate,Clearance Rate, Metabolic,Clearance Rates, Metabolic,Metabolic Clearance Rates,Rate, Metabolic Clearance,Rates, Metabolic Clearance
D008691 Methadone A synthetic opioid that is used as the hydrochloride. It is an opioid analgesic that is primarily a mu-opioid agonist. It has actions and uses similar to those of MORPHINE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1082-3) Amidone,Biodone,Dolophine,Metadol,Metasedin,Methaddict,Methadone Hydrochloride,Methadose,Methex,Phenadone,Phymet,Physeptone,Pinadone,Symoron,Hydrochloride, Methadone
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009294 Narcotics Agents that induce NARCOSIS. Narcotics include agents that cause somnolence or induced sleep (STUPOR); natural or synthetic derivatives of OPIUM or MORPHINE or any substance that has such effects. They are potent inducers of ANALGESIA and OPIOID-RELATED DISORDERS. Analgesics, Narcotic,Narcotic Analgesics,Narcotic,Narcotic Effect,Narcotic Effects,Effect, Narcotic,Effects, Narcotic
D002853 Chromatography, Liquid Chromatographic techniques in which the mobile phase is a liquid. Liquid Chromatography
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D004347 Drug Interactions The action of a drug that may affect the activity, metabolism, or toxicity of another drug. Drug Interaction,Interaction, Drug,Interactions, Drug
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

Mark J Shelton, and Denise Cloen, and Robin DiFrancesco, and Charles S Berenson, and Andrew Esch, and Pascal J de Caprariis, and Branka Palic, and Jane L Schur, and Christopher J L Buggé, and Anders Ljungqvist, and Orlando Espinosa, and Ross G Hewitt
October 2000, Antimicrobial agents and chemotherapy,
Mark J Shelton, and Denise Cloen, and Robin DiFrancesco, and Charles S Berenson, and Andrew Esch, and Pascal J de Caprariis, and Branka Palic, and Jane L Schur, and Christopher J L Buggé, and Anders Ljungqvist, and Orlando Espinosa, and Ross G Hewitt
June 2004, Antiviral therapy,
Mark J Shelton, and Denise Cloen, and Robin DiFrancesco, and Charles S Berenson, and Andrew Esch, and Pascal J de Caprariis, and Branka Palic, and Jane L Schur, and Christopher J L Buggé, and Anders Ljungqvist, and Orlando Espinosa, and Ross G Hewitt
November 2005, The Journal of antimicrobial chemotherapy,
Mark J Shelton, and Denise Cloen, and Robin DiFrancesco, and Charles S Berenson, and Andrew Esch, and Pascal J de Caprariis, and Branka Palic, and Jane L Schur, and Christopher J L Buggé, and Anders Ljungqvist, and Orlando Espinosa, and Ross G Hewitt
January 2002, TreatmentUpdate,
Mark J Shelton, and Denise Cloen, and Robin DiFrancesco, and Charles S Berenson, and Andrew Esch, and Pascal J de Caprariis, and Branka Palic, and Jane L Schur, and Christopher J L Buggé, and Anders Ljungqvist, and Orlando Espinosa, and Ross G Hewitt
April 2003, Journal of acquired immune deficiency syndromes (1999),
Mark J Shelton, and Denise Cloen, and Robin DiFrancesco, and Charles S Berenson, and Andrew Esch, and Pascal J de Caprariis, and Branka Palic, and Jane L Schur, and Christopher J L Buggé, and Anders Ljungqvist, and Orlando Espinosa, and Ross G Hewitt
May 2006, MedGenMed : Medscape general medicine,
Mark J Shelton, and Denise Cloen, and Robin DiFrancesco, and Charles S Berenson, and Andrew Esch, and Pascal J de Caprariis, and Branka Palic, and Jane L Schur, and Christopher J L Buggé, and Anders Ljungqvist, and Orlando Espinosa, and Ross G Hewitt
January 2004, The new microbiologica,
Mark J Shelton, and Denise Cloen, and Robin DiFrancesco, and Charles S Berenson, and Andrew Esch, and Pascal J de Caprariis, and Branka Palic, and Jane L Schur, and Christopher J L Buggé, and Anders Ljungqvist, and Orlando Espinosa, and Ross G Hewitt
January 2008, Antiviral therapy,
Mark J Shelton, and Denise Cloen, and Robin DiFrancesco, and Charles S Berenson, and Andrew Esch, and Pascal J de Caprariis, and Branka Palic, and Jane L Schur, and Christopher J L Buggé, and Anders Ljungqvist, and Orlando Espinosa, and Ross G Hewitt
February 2007, Journal of clinical pharmacology,
Mark J Shelton, and Denise Cloen, and Robin DiFrancesco, and Charles S Berenson, and Andrew Esch, and Pascal J de Caprariis, and Branka Palic, and Jane L Schur, and Christopher J L Buggé, and Anders Ljungqvist, and Orlando Espinosa, and Ross G Hewitt
June 2004, AIDS (London, England),
Copied contents to your clipboard!